Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3072% below fair value
$5.89−0.15 (-2.48%)
Close on Nov 12, 2026Market cap $302.00MP/E –Yield –
Emergent BioSolutions operating margin
Operating margin is operating income as a percentage of revenue.
Emergent BioSolutions's operating margin for the twelve months ending Sep 30, 2026 was -27.7%. For fiscal 2025 it was 13.5%, against -10.4% the year before. The highest annual figure on record is 28.9% in fiscal 2015.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.5% | +23.9 |
| FY2024 | Dec 31, 2024 | -10.4% | +58.8 |
| FY2023 | Dec 31, 2023 | -69.2% | −54.0 |
| FY2022 | Dec 31, 2022 | -15.2% | −34.5 |
| FY2021 | Dec 31, 2021 | 19.2% | −8.6 |
| FY2020 | Dec 31, 2020 | 27.8% | +17.5 |
| FY2019 | Dec 31, 2019 | 10.3% | −1.2 |
| FY2018 | Dec 31, 2018 | 11.5% | −10.7 |
| FY2017 | Dec 31, 2017 | 22.2% | +0.6 |
| FY2016 | Dec 31, 2016 | 21.6% | −7.3 |
| FY2015 | Dec 31, 2015 | 28.9% | +6.9 |
| FY2014 | Dec 31, 2014 | 22.1% | +8.4 |
| FY2013 | Dec 31, 2013 | 13.7% | +3.1 |
| FY2012 | Dec 31, 2012 | 10.6% | −1.1 |
| FY2011 | Dec 31, 2011 | 11.7% | −14.0 |
| FY2010 | Dec 31, 2010 | 25.7% | +8.6 |
| FY2009 | Dec 31, 2009 | 17.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -33.9% | −67.0 |
| Q2 FY2026 | Jun 30, 2026 | -53.4% | −54.5 |
| Q1 FY2026 | Mar 31, 2026 | 6.7% | −15.7 |
| Q4 FY2025 | Dec 31, 2025 | -18.8% | −13.9 |
| Q3 FY2025 | Sep 30, 2025 | 33.1% | +11.1 |
| Q2 FY2025 | Jun 30, 2025 | 1.1% | +81.0 |
| Q1 FY2025 | Mar 31, 2025 | 22.5% | +9.2 |
| Q4 FY2024 | Dec 31, 2024 | -4.9% | +11.0 |
| Q3 FY2024 | Sep 30, 2024 | 22.0% | +111.5 |
| Q2 FY2024 | Jun 30, 2024 | -79.9% | +6.8 |
| Q1 FY2024 | Mar 31, 2024 | 13.2% | +103.1 |
| Q4 FY2023 | Dec 31, 2023 | -15.8% | +0.9 |
| Q3 FY2023 | Sep 30, 2023 | -89.5% | −70.6 |
| Q2 FY2023 | Jun 30, 2023 | -86.7% | −55.2 |
| Q1 FY2023 | Mar 31, 2023 | -89.8% | −92.1 |
| Q4 FY2022 | Dec 31, 2022 | -16.7% | −55.9 |
| Q3 FY2022 | Sep 30, 2022 | -18.9% | −3.3 |
| Q2 FY2022 | Jun 30, 2022 | -31.5% | −33.3 |
| Q1 FY2022 | Mar 31, 2022 | 2.3% | −22.2 |
| Q4 FY2021 | Dec 31, 2021 | 39.1% | −5.1 |
| Q3 FY2021 | Sep 30, 2021 | -15.6% | −31.5 |
| Q2 FY2021 | Jun 30, 2021 | 1.9% | −30.0 |
| Q1 FY2021 | Mar 31, 2021 | 24.5% | +30.5 |
| Q4 FY2020 | Dec 31, 2020 | 44.3% | +22.7 |
| Q3 FY2020 | Sep 30, 2020 | 15.9% | −6.8 |
| Q2 FY2020 | Jun 30, 2020 | 31.9% | +34.8 |
| Q1 FY2020 | Mar 31, 2020 | -6.0% | +8.3 |
| Q4 FY2019 | Dec 31, 2019 | 21.6% | +17.4 |
| Q3 FY2019 | Sep 30, 2019 | 22.7% | +10.4 |
| Q2 FY2019 | Jun 30, 2019 | -2.9% | −33.2 |
| Q1 FY2019 | Mar 31, 2019 | -14.4% | −6.3 |
| Q4 FY2018 | Dec 31, 2018 | 4.1% | −23.3 |
| Q3 FY2018 | Sep 30, 2018 | 12.3% | −19.7 |
| Q2 FY2018 | Jun 30, 2018 | 30.3% | +21.9 |
| Q1 FY2018 | Mar 31, 2018 | -8.1% | −20.8 |
| Q4 FY2017 | Dec 31, 2017 | 27.4% | −6.2 |
| Q3 FY2017 | Sep 30, 2017 | 32.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 8.5% | – |
| Q1 FY2017 | Mar 31, 2017 | 12.8% | – |
| Q4 FY2016 | Dec 31, 2016 | 33.6% | – |
See a number that looks wrong?